Table 3.

Health states according to subgroups in patients treated with ipilimumab

Subgroup	n (%)	36-month r-mean time (months)
		Time on ICI protocol therapy	TFS	TFS difference (95% CI)	Survival after subsequent therapy
Overall	357 (100)	2.6	8.7	NA	10.1
LDH statusa				4.9 (3.1–6.7)
Normal	230 (64)	2.7	10.3		11.7
Elevated	125 (35)	2.4	5.4		7.4
PD-L1 5% status				2.1 (−1.2 to 5.4)
Positive	85 (24)	2.6	10.2		12.0
Negative	225 (63)	2.5	8.1		9.8
BRAF status				−1.1 (−3.1 to 0.9)
Mutant	105 (29)	2.5	7.9		12.6
Wild-type	252 (71)	2.6	9.0		9.1
ECOG performance status				1.7 (−1.1 to 4.6)
0	257 (72)	2.7	9.1		11.6
1–2	100 (28)	2.3	7.5		6.2
Sex				−0.8 (−3.2 to 1.6)
Male	229 (64)	2.5	8.4		10.1
Female	128 (36)	2.6	9.2		10.3

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; NA, not applicable; PD-L1, programmed death ligand 1; TFS, treatment-free survival.

^aUnknown, n=2.

^bUnknown, n=47.